To pursue personalized medicine, BRAF mutations in PTC or RET alterations in MTC can be routinely screened through liquid biopsy to assess sensitivity towards targeted agents and to monitor the onset of resistance. This evidence concerns the gene RET and medullary thyroid gland carcinoma.